IP Verse

Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1 -(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide - EP3317281

The patent EP3317281 was granted to Acerta Pharma on Apr 22, 2020. The application was originally filed on Jul 1, 2016 under application number EP16735945A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3317281

ACERTA PHARMA
Application Number
EP16735945A
Filing Date
Jul 1, 2016
Status
Opposition Rejected
Feb 7, 2025
Grant Date
Apr 22, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KRAUS & LEDERER PARTGMBBJan 21, 2021KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2014155385
DESCRIPTIONWO2013010868
INTERNATIONAL-SEARCH-REPORTWO2013010868
OPPOSITIONEP2734522
OPPOSITIONWO2013010868

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CARR, CHEM. ENG., (1965), vol. 72, pages 163 - 168-
DESCRIPTION- D'CRUZ ET AL., ONCOTARGETS AND THERAPY, (2013), vol. 6, pages 161 - 176-
DESCRIPTION- HAUSNER, INT. J. POWDER METAL!., (1967), vol. 3, pages 7 - 13-
DESCRIPTION- HENDRIKS ET AL., NAT. REV. CANCER, (2014), vol. 14, pages 219 - 231-
DESCRIPTION- JAIN; O'BRIEN, ONCOLOGY, (2012), vol. 26, pages 1146 - 52-
DESCRIPTION- J. A. WOYACH ET AL., BLOOD, (2014), vol. 123, pages 1810 - 17-
DESCRIPTION- J. L. BINET ET AL., CANCER, (1977), vol. 40, pages 855 - 64-
DESCRIPTION- K. R. RAI; T. HAN, HEMATOL. ONCOL. CLIN. NORTH AM., (1990), vol. 4, pages 447 - 56-
DESCRIPTION- LARSEN ET AL., CARBOHYDR. RES., (2003), vol. 338, pages 2325 - 2336-
DESCRIPTION- L. Z. RASSENTI ET AL., N. ENGL. J. MED., (2004), vol. 351, pages 893 - 901-
DESCRIPTION- R. CLAUS ET AL., J. CLIN. ONCOL., (2012), vol. 30, pages 2483 - 91-
DESCRIPTION- R. N. DAMLE ET AL., BLOOD, (1999), vol. 94, pages 1840 - 47-
DESCRIPTION- SMELICK ET AL., MOL. PHARMACEUTICS, (2013), vol. 10, pages 4055 - 4062-
DESCRIPTION- T. J. HAMBLIN ET AL., BLOOD, (1999), vol. 94, pages 1848 - 54-
OPPOSITION- D. CHEN, Hygroscopicity of Pharmaceutical Crystals, (20090100), pages 1 - 126-
OPPOSITION- J. K. GUILLORY, "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids", Polymorphism in Pharmaceutical Solids, (19990000), pages 183 - 226, XP002376368-
OPPOSITION- Tran Phuong H, "Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility", Expert Opinion on Drug Delivery, (20100101), vol. 7, no. 5, pages 647 - 661, XP055976345-
OPPOSITION- S. BYRN et al., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, doi:10.1023/A:1016241927429, pages 945 - 954, XP055399407

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents